U.S. flag

An official website of the United States government

NM_000152.5(GAA):c.2238G>C (p.Trp746Cys) AND Cardiovascular phenotype

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Jan 22, 2024
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV004021024.1

Allele description [Variation Report for NM_000152.5(GAA):c.2238G>C (p.Trp746Cys)]

NM_000152.5(GAA):c.2238G>C (p.Trp746Cys)

Gene:
GAA:alpha glucosidase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q25.3
Genomic location:
Preferred name:
NM_000152.5(GAA):c.2238G>C (p.Trp746Cys)
Other names:
NM_000152.3(GAA):c.2238G>C(p.Trp746Cys); NM_001079803.1(GAA):c.2238G>C(p.Trp746Cys); NM_001079804.1(GAA):c.2238G>C(p.Trp746Cys)
HGVS:
  • NC_000017.11:g.80117016G>C
  • NG_009822.1:g.20461G>C
  • NM_000152.4(GAA):c.2238G>C
  • NM_000152.5:c.2238G>CMANE SELECT
  • NM_001079803.3:c.2238G>C
  • NM_001079804.3:c.2238G>C
  • NP_000143.2:p.Trp746Cys
  • NP_001073271.1:p.Trp746Cys
  • NP_001073272.1:p.Trp746Cys
  • LRG_673t1:c.2238G>C
  • LRG_673:g.20461G>C
  • NC_000017.10:g.78090815G>C
  • NM_000152.3:c.2238G>C
  • NM_000152.4(GAA):c.2238G>C
  • NM_000152.4:c.2238G>C
  • NM_001079803.1:c.2238G>C
  • NM_001079803.2:c.2238G>C
  • NM_001079804.3:c.2238G>C
  • P10253:p.Trp746Cys
Protein change:
W746C
Links:
UniProtKB: P10253#VAR_004311; dbSNP: rs1800312
NCBI 1000 Genomes Browser:
rs1800312
Molecular consequence:
  • NM_000152.5:c.2238G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001079803.3:c.2238G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001079804.3:c.2238G>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Cardiovascular phenotype
Identifiers:
MedGen: CN230736

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV005032503Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)		Pathogenic
(Jan 22, 2024) 		germlineclinical testing

PubMed (18)
[See all records that cite these PMIDs]

Citation Link

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II.

Wan L, Lee CC, Hsu CM, Hwu WL, Yang CC, Tsai CH, Tsai FJ.

J Neurol. 2008 Jun;255(6):831-8. doi: 10.1007/s00415-008-0714-0. Epub 2008 May 6.

PubMed [citation]
PMID:
18458862

Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening.

Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL.

J Pediatr. 2011 Jun;158(6):1023-1027.e1. doi: 10.1016/j.jpeds.2010.11.053. Epub 2011 Jan 13.

PubMed [citation]
PMID:
21232767
See all PubMed Citations (18)

Details of each submission

From Ambry Genetics, SCV005032503.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (18)

Description

The p.W746C pathogenic mutation (also known as c.2238G>C), located in coding exon 15 of the GAA gene, results from a G to C substitution at nucleotide position 2238. The tryptophan at codon 746 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration has been reported in the compound heterozygous and homozygous states in individuals with Pompe disease, mainly late onset disease (Wan L et al. J Neurol, 2008 Jun;255:831-8; Chien YH et al. J Pediatr, 2011 Jun;158:1023-1027.e1; Yang CC et al. Mol Genet Metab, 2011 Nov;104:284-8; Fu Liong H et al. Case Rep Neurol Med, 2014 Jun;2014:926510; Liu X et al. BMC Med Genet, 2014 Dec;15:141; Chu YP et al. Neuromuscul Disord, 2016 Dec;26:873-879; Zhang B et al. Neuropsychiatr Dis Treat, 2016 Mar;12:713-7; Lee JH et al. Neuromuscul Disord, 2017 Jun;27:550-556; Park HJ et al. Clin Genet, 2017 Mar;91:403-410; Kim MS et al. Korean J Pediatr, 2019 Jun;62:224-234; Ficicioglu C et al. Int J Neonatal Screen, 2020 Nov;6:[ePub ahead of print]; Jia X et al. Aging (Albany NY), 2020 Mar;12:4268-4282; Sudrié-Arnaud B et al. Diagnostics (Basel), 2021 Feb;11:[ePub ahead of print]; Zhao HH et al. Ann Transl Med, 2021 Dec;9:1803; Si X et al. CNS Neurosci Ther, 2022 Oct;28:1651-1654; Zhang H et al. Front Neurol, 2022 Mar;13:839263). This alteration has also been shown to reduce enzyme activity in both patient-derived cells and transfected cells (Niño MY et al. JIMD Rep, 2013 Apr;7:39-48; Liu HX et al. Chin Med J (Engl), 2018 Feb;131:448-453). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 12, 2024